Helix BioPharma Corp Sustainability Reports
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies in immuno-oncology for cancer prevention and treatment. The company is actively advancing its proprietary DOS47 technology platform to target solid tumors.
Sector: Manufacturing
Country: Canada
Exchange: Toronto Stock Exchange
LEI: 9845005F4A1779D70B60
6 reports from 2014 to 2025
